2 hours ago
1
The U.S. Federal Trade Commission (FTC) has approved Aurobindo Pharma’s projected acquisition of Pennsylvania-based generic pharmaceutical steadfast Lannett Company.
Valued astatine $250 cardinal connected a cash-free, debt-free ground and inclusive of normalised moving capital, the transaction is expected to adjacent earlier June 2026, Aurobindo Pharma said, announcing connected Monday (June 22, 2026) that its subsidiary, Aurobindo Pharma USA received the FTC approval.
Lannett specialises successful the improvement and commercialisation of a diversified portfolio of complex, non-opioid controlled substances. Its manufacturing tract successful Seymour, Indiana, has the capableness to standard accumulation to astir 4 cardinal doses annually. The enhanced capableness aligns with U.S. argumentation priorities to amended proviso concatenation resilience and summation home pharmaceutical production, Aurobindo said.
The acquisition volition importantly grow Aurobindo USA’s merchandise offering portion adding a U.S.-based manufacturing installation to its network. It volition fortify Aurobindo USA’s home manufacturing footprint, the institution said.
“This acquisition represents a highly compelling strategical and fiscal opportunity. It accelerates our gross growth, strengthens U.S.-based manufacturing capabilities and enhances our presumption successful complex, non-opioid controlled substances. We are assured it volition present contiguous net accretion portion creating semipermanent value,” Aurobindo Pharma USA CEO Swami S. Iyer said.
Lannett Company’s CEO, Tim Crew, said Aurobindo’s marketplace scope and resources volition assistance Lannett, 1 of the oldest generic pharmaceutical companies successful the U.S., marque its portfolio of medicines adjacent much affordable and accessible for patients everywhere.
FTC asks Aurobindo to divest 4 products to Quagen
Separately, the Federal Trade Commission said nether the presumption of its projected consent bid Aurobindo is required to divest 4 generic pharmaceutical products to Quagen Pharmaceuticals, an experienced generic drugmaker.
It is to support American patients from higher cause costs, the Commission said connected June 18. Aurobindo’s acquisition of Lannett would different harvester 2 of a constricted fig of competitors successful the markets for 4 antithetic generic pharmaceutical products that supply captious alleviation for patients, ranging from drugs utilized to forestall organ transplant rejection to tablets that dainty adust rima aft radiation therapy.
The FTC bid follows a ailment alleging that without the divestitures, the acquisition would summation the likelihood of Aurobindo unilaterally exercising marketplace powerfulness successful these 4 cause markets, portion the remaining competitors could prosecute successful coordinated interaction, perchance raising the outgo of generic drugs.
